Order Article Reprints

Partanen A, Waage A, Peceliunas V, Schjesvold F, Anttila P, Säily M, Uttervall K, Putkonen M, Carlson K, Haukas E, et al. Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group. Cancers. 2024; 16(5):1024. https://doi.org/10.3390/cancers16051024

Partanen, Anu, Anders Waage, Valdas Peceliunas, Fredrik Schjesvold, Pekka Anttila, Marjaana Säily, Katarina Uttervall, Mervi Putkonen, Kristina Carlson, Einar Haukas, and et al. 2024. "Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group" Cancers 16, no. 5: 1024. https://doi.org/10.3390/cancers16051024

Partanen, A., Waage, A., Peceliunas, V., Schjesvold, F., Anttila, P., Säily, M., Uttervall, K., Putkonen, M., Carlson, K., Haukas, E., Sankelo, M., Szatkowski, D., Hansson, M., Marttila, A., Svensson, R., Axelsson, P., Lauri, B., Mikkola, M., Karlsson, C., ... Silvennoinen, R. (2024). Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group. Cancers, 16(5), 1024. https://doi.org/10.3390/cancers16051024